TickerGuard
Buy Day today: Neutral (56) Mixed market breadth · no major macro event
EXEL

Exelixis Inc

Healthcare · Biotechnology

58.20$ +0.4% vs. previous close Closing price · As of: Sep 25, 2026

Statements

Income Statement

Exelixis Inc (EXEL) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 629 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement EXEL
Line item Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 LTM
472 480 425 637 540 567 555 568 598 599 611 629 2,436
19 22 21 18 17 20 19 19 19 26 20 21 86
453 458 404 620 522 547 536 549 579 572 591 608 2,350
333 245 228 211 223 249 212 200 199 213 200 212 824
138 91 114 132 112 91 137 135 124 71 140 148 482
471 376 375 344 386 384 349 335 343 337 340 360 1,379
-18 82 29 276 136 163 187 214 237 235 251 248 972
– 26 – – – – – – – – – – –
5.8 103 49 293 155 185 206 230 252 253 268 263 1,035
4.8 18 12 67 37 45 46 46 59 8.2 57 51 175
1.0 86 37 226 118 140 160 185 194 245 210 212 861
12 110 69 284 195 171 213 238 260 243 275 263 1,040

LTM = last twelve months (sum of the four most recent quarters).

Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?